Wickham’s Striae (Lichen Planus) – A Comprehensive Medical Guide
Overview
Wickham’s striae are the characteristic fine, white‑lacy lines that appear on the surface of the papules in lichen planus, a chronic inflammatory disease affecting the skin, mucous membranes, hair follicles, and nails. The term “Wickham’s striae” honors British dermatologist Thomas Wickham, who first described the linear pattern in 1860.
Lichen planus (LP) can affect anyone, but certain groups are more frequently diagnosed:
- Age: Most cases arise in middle‑aged adults (30‑60 years).
- Sex: Slight female predominance (≈55 % of cases).
- Ethnicity: Higher prevalence reported in people of Hispanic and Asian descent.
Worldwide prevalence is estimated at **1–2 %** of the general population, with about **0.5 %** developing the mucosal (oral) form that carries a small risk of malignancy [1] CDC, 2023.
Symptoms
The clinical picture varies depending on the site involved (skin, mouth, genitals, nails, scalp). Below is a comprehensive list of symptoms, grouped by location.
Skin (Cutaneous) Lichen Planus
- Violaceous (purple‑brown) polygonal papules – often flat‑topped and 2–5 mm in diameter.
- Wickham’s striae – fine, whitish, network‑like lines visible on the papules when examined with a dermatoscope or close inspection.
- Itching (pruritus) – common, may be severe and disturb sleep.
- Koebner phenomenon – new lesions appearing at sites of skin injury (scratches, pressure).
- Arranged in a linear or “flag‑pole” pattern on wrists, forearms, and ankles.
Mucosal Lichen Planus
- Oral lesions – white, lace‑like (Wickham’s) striae on buccal mucosa, tongue, or gingiva; may be erosive, causing a burning sensation.
- Genital lesions – white plaques or erosions on the vulva or penis, often painful during intercourse.
- Ocular involvement – conjunctival redness, dry eye, or rarely scarring.
Nail (Ungual) Lichen Planus
- Longitudinal ridging, thinning, or splitting of nails.
- Red‑brown discoloration (pterygium formation) and possible loss of the nail plate.
Hair (Scalp) Lichen Planus – “Lichen Planopilaris”
- Inflammatory scarring alopecia – patches of hair loss with perifollicular erythema.
- Peripheral white scaling and itching.
Causes and Risk Factors
Exact cause remains unknown, but research points to an autoimmune reaction in which T‑cells mistakenly attack basal keratinocytes. Contributing factors include:
- Genetic predisposition: Certain HLA types (e.g., HLA‑DR1) increase susceptibility [2] NIH, 2021.
- Viral triggers: Hepatitis C infection is linked to a 2–3‑fold higher odds of LP [3] WHO, 2022.
- Medications (drug‑induced LP): Common culprits are beta‑blockers, thiazide diuretics, non‑steroidal anti‑inflammatory drugs (NSAIDs), and certain antimalarials.
- Contact allergens: Dental amalgam, gold, and certain cosmetics may precipitate oral LP.
- Other autoimmune diseases: Higher prevalence among patients with lupus, rheumatoid arthritis, or autoimmune thyroid disease.
Diagnosis
Diagnosis is primarily clinical, relying on the classic appearance of Wickham’s striae and the distribution of lesions. Supporting tools include:
Physical Examination
- Dermatoscopic evaluation – highlights the reticular white lines of Wickham’s striae.
- Assessment for Koebner phenomenon or nail involvement.
Skin Biopsy
When the presentation is atypical, a 4‑mm punch biopsy is taken. Histopathology typically shows:
- Hyperkeratosis and “saw‑tooth” rete ridges.
- Band‑like lymphocytic infiltrate at the dermal‑epidermal junction.
- Degeneration of basal keratinocytes (Civatte bodies).
Laboratory Tests (Selective)
- Hepatitis C serology – recommended for all newly diagnosed LP patients [4] CDC, 2022.
- Direct immunofluorescence of oral lesions – helps differentiate from pemphigus or lupus.
- Complete blood count and metabolic panel if systemic therapy is considered.
Treatment Options
Therapy aims to relieve symptoms, control inflammation, and prevent scarring. Treatment is individualized based on severity, location, and patient comorbidities.
Topical Therapies
- High‑potency corticosteroids (e.g., clobetasol 0.05 % ointment) – first‑line for cutaneous plaques; apply once or twice daily for 2–4 weeks.
- Topical calcineurin inhibitors (tacrolimus 0.1 % or pimecrolimus 1 %) – useful for intertriginous areas and oral mucosa where steroids cause atrophy.
- Vitamin D analogs (calcipotriol) – adjunctive for resistant skin lesions.
Systemic Medications
- Oral corticosteroids – short courses (prednisone 0.5 mg/kg) for severe flare‑ups; taper to avoid adrenal suppression.
- Antimetabolites – azathioprine 1–2 mg/kg/day or mycophenolate mofetil 1–2 g/day for chronic disease.
- Retinoids – acitretin 25–35 mg daily; effective for extensive or refractory cutaneous LP.
- Biologic agents – off‑label use of dupilumab or secukinumab has shown promise in case series, especially for mucosal disease.
Procedural Options
- Phototherapy – narrow‑band UVB 2–3 times weekly; useful for widespread skin involvement.
- Laser therapy – CO₂ laser for oral erosive lesions; pulsed‑dye laser for hypertrophic plaques.
- Intralesional steroid injections – triamcinolone acetonide (10 mg/ml) for isolated thick plaques or nail matrix disease.
Lifestyle and Supportive Measures
- Gentle skin care: fragrance‑free moisturizers, mild soaps.
- Avoid scratching; keep nails trimmed to reduce secondary infection.
- Stress‑reduction techniques (mindfulness, yoga) – stress can exacerbate autoimmune activity.
Living with Wickham’s Striae (Lichen Planus)
Chronic diseases require day‑to‑day strategies to maintain quality of life.
- Skin protection: Use cotton clothing, avoid tight straps, and protect exposed skin from sunburn (broad‑spectrum SPF 30+).
- Oral care: Rinse with alcohol‑free chlorhexidine mouthwash, use a soft‑bristled toothbrush, and avoid spicy or acidic foods that irritate lesions.
- Regular follow‑up: Dermatology visits every 3–6 months for monitoring; more frequent if on systemic immunosuppressants.
- Psychological support: Join support groups or counseling; chronic itching and visible lesions can affect self‑esteem.
- Document flare triggers: Keep a diary of foods, medications, stress events, and environmental exposures to identify patterns.
Prevention
Because the exact cause is unknown, primary prevention is limited. However, risk can be reduced by:
- Screening and treating hepatitis C infection promptly.
- Reviewing medication lists with a physician; discuss alternatives if a drug‑induced rash is suspected.
- Maintaining good oral hygiene and limiting contact with known dental allergens (e.g., replace amalgam fillings with composite if appropriate).
- Protecting the skin from trauma – avoid harsh scrubbing, use protective padding when engaging in sports.
Complications
If left untreated or poorly controlled, lichen planus can lead to:
- Scarring alopecia (permanent hair loss) from lichen planopilaris.
- Permanent nail dystrophy or loss.
- Oral cancer: Chronic erosive oral LP carries a modest increased risk of squamous cell carcinoma (approximately 0.5–1 % over 10 years) [5] Mayo Clinic, 2023.
- Secondary infection: Excoriated skin or ulcerated mucosa may become bacterial or fungal infected.
- Psychosocial impact: Persistent itching and visible lesions can lead to anxiety, depression, and social isolation.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden swelling of the lips, tongue, or throat that makes breathing or swallowing difficult (possible anaphylactoid reaction to medication).
- Rapidly spreading blistering rash with intense pain (might indicate Stevens‑Johnson syndrome, a severe drug reaction that can be triggered by medications used for LP).
- Fever ≥ 38.5 °C (101.3 °F) accompanied by a widespread rash, indicating possible infection or drug reaction.
- Severe, unrelenting pain in the mouth or genital area that is not controlled with prescribed medication and is affecting vital functions (e.g., inability to eat or hydrate).
These situations require immediate medical evaluation to prevent life‑threatening complications.
References
- Centers for Disease Control and Prevention (CDC). “Lichen Planus Fact Sheet.” Updated 2023.
- National Institutes of Health (NIH). “Genetic Susceptibility in Lichen Planus.” *J Invest Dermatol*, 2021.
- World Health Organization (WHO). “Hepatitis C and Extra‑hepatic Manifestations.” 2022.
- CDC. “Guidelines for Testing Hepatitis C in Patients with Dermatologic Conditions.” 2022.
- Mayo Clinic. “Oral Lichen Planus and Cancer Risk.” 2023.